Lifecore Biomedical
LFCR
86 hedge funds and large institutions have $220M invested in Lifecore Biomedical in 2022 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 28 increasing their positions, 32 reducing their positions, and 7 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
2.16% less ownership
Funds ownership: 85.76% → 83.6% (-2.2%)
4% less funds holding
Funds holding: 90 → 86 (-4)
13% less repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 32
13% less capital invested
Capital invested by funds: $252M → $220M (-$32.1M)
57% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 7
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $71K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
2L
22NW LP
Seattle,
Washington
|
+$4.2M |
| 2 |
PAIM
Punch & Associates Investment Management
Edina,
Minnesota
|
+$3.38M |
| 3 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
+$820K |
| 4 |
Boston Partners
Boston,
Massachusetts
|
+$161K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$157K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ICM
ISZO Capital Management
New York
|
-$7.23M |
| 2 |
ERSOT
Employees Retirement System of Texas
Austin,
Texas
|
-$1.7M |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$1.09M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
-$994K |
| 5 |
BlackRock
New York
|
-$964K |
LFCR Hedge Fund Activity: Q3 2022 in Review
86 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Lifecore Biomedical (LFCR) for Q3 2022, worth a combined $220M — down 13% from $252M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of LFCR and 3 opened new positions — a net loss of 4 holders — while 32 trimmed existing stakes and 28 added.
The largest buyer was 22NW LP, adding an estimated $4.2M. The largest seller was ISZO Capital Management, cutting an estimated $7.23M.
- 86 institutional investors held Lifecore Biomedical (LFCR) as of Q3 2022, down from 90 in Q2 2022.
- Funds reported $220M of Lifecore Biomedical stock for Q3 2022, down 13% quarter-over-quarter.
- 3 funds opened new Lifecore Biomedical positions in Q3 2022 and 7 closed out, a net change of -4 holders.
- The largest Lifecore Biomedical buyer in Q3 2022 was 22NW LP, an estimated $4.2M added.
- The largest Lifecore Biomedical seller in Q3 2022 was ISZO Capital Management, an estimated $7.23M sold.
Based on aggregated 13F filings for Q3 2022.